The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2020

Filed:

Jun. 14, 2017
Applicant:

Sinonutraceutical Co., Ltd., Pudong New District, Shanghai, CN;

Inventors:

Maojian Gu, Shanghai, CN;

Jianmei Su, Shanghai, CN;

Assignee:

SinoNutraceutical Co., Ltd., Pudong New District, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/20 (2006.01); C07C 403/24 (2006.01); A61P 27/02 (2006.01); A23L 33/105 (2016.01); A61K 47/12 (2006.01); A61K 31/23 (2006.01); A61K 47/02 (2006.01); A61K 31/047 (2006.01); A61K 31/015 (2006.01); A61K 47/40 (2006.01); A61K 47/26 (2006.01); A61P 27/12 (2006.01); A61P 27/10 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07C 403/24 (2013.01); A23L 33/105 (2016.08); A61K 9/0056 (2013.01); A61K 9/20 (2013.01); A61K 31/015 (2013.01); A61K 31/047 (2013.01); A61K 31/23 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61P 27/02 (2018.01); A61P 27/10 (2018.01); A61P 27/12 (2018.01); A23V 2002/00 (2013.01);
Abstract

Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, β-carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to β-carotene is 1:0.1-100. In the present invention, by cooperatively using lutein/lutein ester and β-carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By eating the product, visual power can be obviously enhanced, the ocular blood flow is increased, and eye muscle fatigue is alleviated, and accordingly the morbidities of cataract, senile niacula lutea retinae lesion and adolescent myopia are reduced.


Find Patent Forward Citations

Loading…